Phase III, Long-term, Open-label Safety Study of Z-338

PHASE3CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 30, 2016

Study Completion Date

April 30, 2017

Conditions
Dyspepsia
Interventions
DRUG

Z-338

100mg TID

Trial Locations (36)

Unknown

Zeria Investigative site, Leuven

Zeria Investigative Site, Plovdiv

Zeria Investigative Sites, Sofia

Zeria Investigative site, Varna

Zeria Invetigative Site, Liepāja

Zeria Investivgative SIte, Limbaži

Zeria Investigative Sites, Riga

Zeria Investigative Site, Alytus

Zeria Investigative Sites, Kaunas

Zeria Investigative Site, Klaipėda

Zeria Investigative Site, Vilnius

Zeria Investigative Site, Brasov

Zeria Investigative Sites, Bucharest

Zeria Investigative Sites, Cluj-Napoca

Zeria Investigative Site, Sibiu

Zeria Investigative Site, Târgu Mureş

Zeria Investigative Sites, Timișoara

Zeria Investigative Site, Kazan'

Zeria Investigative Site, Ryazan

Zeria Investigative Site, Saratov

Zeria Investigative Site, Yaroslavl

Zeria Investigative sites, Bratislava

Zeria Investigative sites, Košice

Zeria Investigative Site, Malacky

Zeria Investigative Site, Martin

Zeria Investigative Site, Nitra

Zeria Investigative Site, Prešov

Zeria Investigative Site, Trnava

Zeria Investigative Site, Gothenburg

Zeria Investigative Sites, Stockholm

Zeria Investigative Site, Dnipropetrovsk

Zeria Investigative Site, Kyiv

Zeria Investigative Site, Vinnytsia

Zeria Investigative site, Barnstaple

Zeria Investigative site, Bath

Zeria Investigative Site, Royal Leamington Spa

Sponsors
All Listed Sponsors
lead

Zeria Pharmaceutical

INDUSTRY

NCT01973790 - Phase III, Long-term, Open-label Safety Study of Z-338 | Biotech Hunter | Biotech Hunter